Advertisement

Fall 58: Spätschäden – 64 Jahre, ♀, DM Typ 2, Krebsrisiko

  • Lars Kihm
Chapter

Zusammenfassung

Eine 64-jährige Typ-2-Diabetikerin wird aktuell mit einem BOT mit Insulin Glargin und Metformin behandelt. Ihre jüngere Schwester ist rezent an einem Mammakarzinom verstorben. Sie hat jetzt Angst. Was sagen die Studien?

Literatur

  1. Bordeleau L, Yakubovich N, Dagenais GR, Rosenstock J, Probstfield J, Chang YuP, Ryden LE, Pirags V, Spinas GA, Birkeland KI, Ratner RE, Marin-Neto JA, Keltai M, Riddle MC, Bosch J, Yusuf S, Gerstein HC, Investigators OT (2014) The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. Diabetes care 37(5):1360–1366.  https://doi.org/10.2337/dc13-1468CrossRefPubMedGoogle Scholar
  2. Currie CJ, Poole CD, Gale EA (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52(9):1766–1777.  https://doi.org/10.1007/s00125-009-1440-6CrossRefPubMedGoogle Scholar
  3. Gallagher EJ, Zelenko Z, Tobin-Hess A, Werner U, Tennagels N, LeRoith D (2016) Non-metabolisable insulin glargine does not promote breast cancer growth in a mouse model of type 2 diabetes. Diabetologia 59(9):2018–2025.  https://doi.org/10.1007/s00125-016-4000-xCrossRefPubMedPubMedCentralGoogle Scholar
  4. Hemkens LG, Grouven U, Bender R, Gunster C, Gutschmidt S, Selke GW, Sawicki PT (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52(9):1732–1744.  https://doi.org/10.1007/s00125-009-1418-4CrossRefPubMedPubMedCentralGoogle Scholar
  5. Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G (2009) Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 52(9):1745–1754.  https://doi.org/10.1007/s00125-009-1444-2CrossRefPubMedGoogle Scholar
  6. Larsson SC, Mantzoros CS, Wolk A (2007) Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 121(4):856–862.  https://doi.org/10.1002/ijc.22717CrossRefPubMedGoogle Scholar
  7. Stammberger I, Essermeant L (2012) Insulin glargine: a reevaluation of rodent carcinogenicity findings. Int J Toxicol 31(2):137–142.  https://doi.org/10.1177/1091581811431111CrossRefPubMedPubMedCentralGoogle Scholar
  8. Swinnen SG, Simon AC, Holleman F, Hoekstra JB, Devries JH (2011) Insulin detemir versus insulin glargine for type 2 diabetes mellitus. The Cochrane database of systematic reviews (7):CD006383.  https://doi.org/10.1002/14651858.cd006383.pub2
  9. Wu JW, Azoulay L, Majdan A, Boivin JF, Pollak M, Suissa S (2017) Long-term use of long-acting insulin analogs and breast cancer incidence in women with type 2 diabetes. J Clin Oncol: official J American Society of Clinical Oncology 35(32):3647–3653.  https://doi.org/10.1200/JCO.2017.73.4491CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Abteilung Innere Medizin IMedizinische UniversitätsklinikHeidelbergDeutschland

Personalised recommendations